Thirty-seven trials included in this literature review administered L-carnitine intravenously while 12 trials used oral L-carnitine (Chen 2014)
Healthy growing follicles exhibit resistance to granulosa cells apoptosis, whereas in early atretic follicles, apoptosis begins in the inner granulosa cells layer and progressively affects most granulosa cells, leading to follicular atresia (Tilly et al., 1991)
PMID: 15781745 Roman MJ, Devereux RB, Kramer-Fox R, Spitzer MC
Sources Novo Nordisk NDA filing for CagriSema, December 18, 2025 American Diabetes Association REDEFINE-1 and REDEFINE-2 results, ADA 2026 Scientific Sessions HCPLive REDEFINE-1 Phase 3 safety and efficacy data Clinical Trials Arena REDEFINE-4: CagriSema vs tirzepatide head-to-head, February 2026 Life Science Daily News CagriSema FDA review timeline and NDA update, July 2026 PharmExec REDEFINE-1 results: CagriSema falls short of 25% weight loss target Drugs.com CagriSema FDA approval status history New England Journal of Medicine REDEFINE-1 full publication (presented at ADA 2026) Novo Nordisk REIMAGINE Phase 3 diabetes trial results, ADA 2026 and The Lancet FDA Wegovy (semaglutide) prescribing information, 2025 Related reading on Heally: What is Wegovy HD
